BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z, Hazan-Halevy I, Wang Y, Kantarjian HM, Priebe W. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res. 2007;67:11291-11299. [PMID: 18056455 DOI: 10.1158/0008-5472.can-07-0593] [Cited by in Crossref: 95] [Cited by in F6Publishing: 55] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Daniel JM, Dutzmann J, Bielenberg W, Widmer-Teske R, Gündüz D, Hamm CW, Sedding DG. Inhibition of STAT3 signaling prevents vascular smooth muscle cell proliferation and neointima formation. Basic Res Cardiol 2012;107:261. [PMID: 22418922 DOI: 10.1007/s00395-012-0261-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
2 Zhou X, Ren Y, Liu A, Jin R, Jiang Q, Huang Y, Kong L, Wang X, Zhang L. WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR-21 axis. Sci Rep 2014;4:7461. [PMID: 25514838 DOI: 10.1038/srep07461] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
3 Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer GE Jr, Sampson JH, Priebe W, Heimberger AB. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 2008;14:5759-68. [PMID: 18794085 DOI: 10.1158/1078-0432.CCR-08-0377] [Cited by in Crossref: 88] [Cited by in F6Publishing: 59] [Article Influence: 6.3] [Reference Citation Analysis]
4 Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells. Int J Cancer 2017;141:2076-81. [PMID: 28722170 DOI: 10.1002/ijc.30892] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
5 Brachet-Botineau M, Polomski M, Neubauer HA, Juen L, Hédou D, Viaud-Massuard MC, Prié G, Gouilleux F. Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers. Cancers (Basel) 2020;12:E240. [PMID: 31963765 DOI: 10.3390/cancers12010240] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
6 Mukthavaram R, Ouyang X, Saklecha R, Jiang P, Nomura N, Pingle SC, Guo F, Makale M, Kesari S. Effect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres. J Transl Med 2015;13:269. [PMID: 26283544 DOI: 10.1186/s12967-015-0627-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
7 Malińska M, Fokt I, Priebe W, Woźniak K. Bromine Atom Interactions in Biologically Active Acrylamide Derivatives. Crystal Growth & Design 2015;15:2632-42. [DOI: 10.1021/cg501598h] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
8 Lutterberg K, Kleinwort KJH, Hobmaier BF, Hauck SM, Nüske S, Scholz AM, Deeg CA. A Functionally Different Immune Phenotype in Cattle Is Associated With Higher Mastitis Incidence. Front Immunol 2018;9:2884. [PMID: 30574152 DOI: 10.3389/fimmu.2018.02884] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia. Leuk Lymphoma 2018;59:2686-91. [PMID: 29465264 DOI: 10.1080/10428194.2018.1439167] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
10 Seo IA, Lee HK, Shin YK, Lee SH, Seo SY, Park JW, Park HT. Janus Kinase 2 Inhibitor AG490 Inhibits the STAT3 Signaling Pathway by Suppressing Protein Translation of gp130. Korean J Physiol Pharmacol. 2009;13:131-138. [PMID: 19885008 DOI: 10.4196/kjpp.2009.13.2.131] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
11 Kong LY, Wu AS, Doucette T, Wei J, Priebe W, Fuller GN, Qiao W, Sawaya R, Rao G, Heimberger AB. Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin Cancer Res 2010;16:5722-33. [PMID: 20921210 DOI: 10.1158/1078-0432.CCR-10-1693] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
12 Chan D, Koren-Michowitz M. Update on JAK2 Inhibitors in Myeloproliferative Neoplasm. Ther Adv Hematol 2011;2:61-71. [PMID: 23556077 DOI: 10.1177/2040620711401646] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
13 Grabenstatter HL, Del Angel YC, Carlsen J, Wempe MF, White AM, Cogswell M, Russek SJ, Brooks-Kayal AR. The effect of STAT3 inhibition on status epilepticus and subsequent spontaneous seizures in the pilocarpine model of acquired epilepsy. Neurobiol Dis 2014;62:73-85. [PMID: 24051278 DOI: 10.1016/j.nbd.2013.09.003] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 5.6] [Reference Citation Analysis]
14 Xie B, Zhang L, Hu W, Fan M, Jiang N, Duan Y, Jing D, Xiao W, Fragoso RC, Lam KS, Sun LQ, Li JJ. Dual blockage of STAT3 and ERK1/2 eliminates radioresistant GBM cells. Redox Biol 2019;24:101189. [PMID: 30986607 DOI: 10.1016/j.redox.2019.101189] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
15 Lee H, Jeong AJ, Ye SK. Highlighted STAT3 as a potential drug target for cancer therapy. BMB Rep 2019;52:415-23. [PMID: 31186087 [PMID: 31186087 DOI: 10.5483/bmbrep.2019.52.7.152] [Cited by in Crossref: 48] [Article Influence: 24.0] [Reference Citation Analysis]
16 Judd LM, Menheniott TR, Ling H, Jackson CB, Howlett M, Kalantzis A, Priebe W, Giraud AS. Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo. PLoS One. 2014;9:e95993. [PMID: 24804649 DOI: 10.1371/journal.pone.0095993] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 7.4] [Reference Citation Analysis]
17 Bellucci R, Nguyen HN, Martin A, Heinrichs S, Schinzel AC, Hahn WC, Ritz J. Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. J Clin Invest 2012;122:2369-83. [PMID: 22684105 DOI: 10.1172/JCI58457] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
18 Chung SY, Chen YH, Lin PR, Chao TC, Su JC, Shiau CW, Su Y. Two novel SHP-1 agonists, SC-43 and SC-78, are more potent than regorafenib in suppressing the in vitro stemness of human colorectal cancer cells. Cell Death Discov 2018;4:25. [PMID: 30109144 DOI: 10.1038/s41420-018-0084-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
19 Ou A, Ott M, Fang D, Heimberger AB. The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma. Cancers (Basel) 2021;13:437. [PMID: 33498872 DOI: 10.3390/cancers13030437] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Zhang SP, Wang Z, Wang LX, Liu SJ. AG490: An inhibitor of hepcidin expression in vivoWorld J Gastroenterol 2011; 17(45): 5032-5034 [PMID: 22174555 DOI: 10.3748/wjg.v17.i45.5032] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
21 Kirabo A, Embury J, Kiss R, Polgár T, Gali M, Majumder A, Bisht KS, Cogle CR, Keseru GM, Sayeski PP. The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo. J Biol Chem 2011;286:4280-91. [PMID: 21127060 DOI: 10.1074/jbc.M110.200774] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
22 Wu J, Dong F, Wang RA, Wang J, Zhao J, Yang M, Gong W, Cui R, Dong L. Central role of cellular senescence in TSLP-induced airway remodeling in asthma. PLoS One. 2013;8:e77795. [PMID: 24167583 DOI: 10.1371/journal.pone.0077795] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
23 Ou-Yang H, Wu SC, Sung LY, Yang SH, Yang SH, Chong KY, Chen CM. STAT3 Is an Upstream Regulator of Granzyme G in the Maternal-To-Zygotic Transition of Mouse Embryos. Int J Mol Sci 2021;22:E460. [PMID: 33466434 DOI: 10.3390/ijms22010460] [Reference Citation Analysis]
24 Jatiani SS, Cosenza SC, Reddy MV, Ha JH, Baker SJ, Samanta AK, Olnes MJ, Pfannes L, Sloand EM, Arlinghaus RB, Reddy EP. A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. Genes Cancer 2010;1:331-45. [PMID: 20717479 DOI: 10.1177/1947601910371337] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
25 Xiong A, Yang Z, Shen Y, Zhou J, Shen Q. Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention. Cancers (Basel). 2014;6:926-957. [PMID: 24743778 DOI: 10.3390/cancers6020926] [Cited by in Crossref: 169] [Cited by in F6Publishing: 157] [Article Influence: 21.1] [Reference Citation Analysis]
26 Unsal Tan O, Zengin M. Insights into the chemistry and therapeutic potential of acrylonitrile derivatives. Arch Pharm (Weinheim) 2021;:e202100383. [PMID: 34763365 DOI: 10.1002/ardp.202100383] [Reference Citation Analysis]
27 Lee H, Pal SK, Reckamp K, Figlin RA, Yu H. STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol 2011;344:41-59. [PMID: 20517723 DOI: 10.1007/82_2010_51] [Cited by in Crossref: 32] [Cited by in F6Publishing: 64] [Article Influence: 2.9] [Reference Citation Analysis]
28 Sai K, Wang S, Balasubramaniyan V, Conrad C, Lang FF, Aldape K, Szymanski S, Fokt I, Dasgupta A, Madden T, Guan S, Chen Z, Alfred Yung WK, Priebe W, Colman H. Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway. J Neurooncol 2012;107:487-501. [PMID: 22249692 DOI: 10.1007/s11060-011-0786-z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
29 Li P, Harris D, Liu Z, Liu J, Keating M, Estrov Z. Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PLoS One 2010;5:e11859. [PMID: 20686606 DOI: 10.1371/journal.pone.0011859] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 3.6] [Reference Citation Analysis]
30 Sayyah J, Sayeski PP. Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies. Curr Oncol Rep 2009;11:117-24. [PMID: 19216843 DOI: 10.1007/s11912-009-0018-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
31 Genini D, Brambilla L, Laurini E, Merulla J, Civenni G, Pandit S, D'Antuono R, Perez L, Levy DE, Pricl S, Carbone GM, Catapano CV. Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells. Proc Natl Acad Sci U S A 2017;114:E4924-33. [PMID: 28584133 DOI: 10.1073/pnas.1615730114] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 10.6] [Reference Citation Analysis]
32 Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells. Oncotarget 2018;9:21268-80. [PMID: 29765537 DOI: 10.18632/oncotarget.25066] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
33 Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs. 2009;18:45-56. [PMID: 19053881 DOI: 10.1517/13543780802565791] [Cited by in Crossref: 291] [Cited by in F6Publishing: 279] [Article Influence: 22.4] [Reference Citation Analysis]
34 Butturini E, Carcereri de Prati A, Boriero D, Mariotto S. Natural Sesquiterpene Lactones Enhance Chemosensitivity of Tumor Cells through Redox Regulation of STAT3 Signaling. Oxid Med Cell Longev 2019;2019:4568964. [PMID: 31781335 DOI: 10.1155/2019/4568964] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
35 Nagao T, Oshikawa G, Wu N, Kurosu T, Miura O. DNA damage stress and inhibition of Jak2-V617F cause its degradation and synergistically induce apoptosis through activation of GSK3β. PLoS One 2011;6:e27397. [PMID: 22087308 DOI: 10.1371/journal.pone.0027397] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
36 Kim BG, Yoo JY, Kim TH, Shin JH, Langenheim JF, Ferguson SD, Fazleabas AT, Young SL, Lessey BA, Jeong JW. Aberrant activation of signal transducer and activator of transcription-3 (STAT3) signaling in endometriosis. Hum Reprod 2015;30:1069-78. [PMID: 25750101 DOI: 10.1093/humrep/dev050] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 7.0] [Reference Citation Analysis]
37 Zhang L, Peterson TE, Lu VM, Parney IF, Daniels DJ. Antitumor activity of novel pyrazole-based small molecular inhibitors of the STAT3 pathway in patient derived high grade glioma cells. PLoS One 2019;14:e0220569. [PMID: 31361777 DOI: 10.1371/journal.pone.0220569] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
38 Horiguchi A, Asano T, Kuroda K, Sato A, Asakuma J, Ito K, Hayakawa M, Sumitomo M, Asano T. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer 2010;102:1592-9. [PMID: 20461084 DOI: 10.1038/sj.bjc.6605691] [Cited by in Crossref: 81] [Cited by in F6Publishing: 72] [Article Influence: 6.8] [Reference Citation Analysis]
39 Delbue D, Lebenheim L, Cardoso-Silva D, Dony V, Krug SM, Richter JF, Manna S, Muñoz M, Wolk K, Heldt C, Heimesaat MM, Sabat R, Siegmund B, Schumann M. Reprogramming Intestinal Epithelial Cell Polarity by Interleukin-22. Front Med (Lausanne) 2021;8:656047. [PMID: 33912578 DOI: 10.3389/fmed.2021.656047] [Reference Citation Analysis]
40 Nazio F, Po A, Abballe L, Ballabio C, Diomedi Camassei F, Bordi M, Camera A, Caruso S, Caruana I, Pezzullo M, Ferraina C, Milletti G, Gianesello M, Reddel S, De Luca CD, Ceglie D, Marinelli S, Campello S, Papaleo E, Miele E, Cacchione A, Carai A, Vinci M, Velardi E, De Angelis B, Tiberi L, Quintarelli C, Mastronuzzi A, Ferretti E, Locatelli F, Cecconi F. Targeting cancer stem cells in medulloblastoma by inhibiting AMBRA1 dual function in autophagy and STAT3 signalling. Acta Neuropathol 2021;142:537-64. [PMID: 34302498 DOI: 10.1007/s00401-021-02347-7] [Reference Citation Analysis]
41 Barosi G, Rosti V. Novel strategies for patients with chronic myeloproliferative disorders. Curr Opin Hematol 2009;16:129-34. [PMID: 19468275 DOI: 10.1097/MOH.0b013e3283257a9e] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
42 Chen Q, Lv J, Yang W, Xu B, Wang Z, Yu Z, Wu J, Yang Y, Han Y. Targeted inhibition of STAT3 as a potential treatment strategy for atherosclerosis. Theranostics 2019;9:6424-42. [PMID: 31588227 DOI: 10.7150/thno.35528] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
43 Reitsma JM, Sato H, Nevels M, Terhune SS, Paulus C. Human cytomegalovirus IE1 protein disrupts interleukin-6 signaling by sequestering STAT3 in the nucleus. J Virol 2013;87:10763-76. [PMID: 23903834 DOI: 10.1128/JVI.01197-13] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
44 Hazan-Halevy I, Harris D, Liu Z, Liu J, Li P, Chen X, Shanker S, Ferrajoli A, Keating MJ, Estrov Z. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood 2010;115:2852-63. [PMID: 20154216 DOI: 10.1182/blood-2009-10-230060] [Cited by in Crossref: 144] [Cited by in F6Publishing: 137] [Article Influence: 12.0] [Reference Citation Analysis]
45 Dorritie KA, McCubrey JA, Johnson DE. STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia 2014;28:248-57. [PMID: 23797472 DOI: 10.1038/leu.2013.192] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
46 Rozovski U, Grgurevic S, Bueso-Ramos C, Harris DM, Li P, Liu Z, Wu JY, Jain P, Wierda W, Burger J, O'Brien S, Jain N, Ferrajoli A, Keating MJ, Estrov Z. Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells. Mol Cancer Res 2015;13:944-53. [PMID: 25733697 DOI: 10.1158/1541-7786.MCR-14-0412] [Cited by in Crossref: 45] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
47 Arshad S, Naveed M, Ullia M, Javed K, Butt A, Khawar M, Amjad F. Targeting STAT-3 signaling pathway in cancer for development of novel drugs: Advancements and challenges. Genet Mol Biol 2020;43:e20180160. [PMID: 32167126 DOI: 10.1590/1678-4685-GMB-2018-0160] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
48 Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Priebe W. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther. 2010;9:67-78. [PMID: 20053772 DOI: 10.1158/1535-7163.mct-09-0734] [Cited by in Crossref: 168] [Cited by in F6Publishing: 122] [Article Influence: 14.0] [Reference Citation Analysis]
49 Linher-Melville K, Singh G. The transcriptional responsiveness of LKB1 to STAT-mediated signaling is differentially modulated by prolactin in human breast cancer cells. BMC Cancer 2014;14:415. [PMID: 24913037 DOI: 10.1186/1471-2407-14-415] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
50 Tabata T, Petitt M, Fang-Hoover J, Zydek M, Pereira L. Persistent Cytomegalovirus Infection in Amniotic Membranes of the Human Placenta. Am J Pathol 2016;186:2970-86. [PMID: 27638253 DOI: 10.1016/j.ajpath.2016.07.016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
51 Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB, Tweardy DJ. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood 2011;117:5701-9. [PMID: 21447830 DOI: 10.1182/blood-2010-04-280123] [Cited by in Crossref: 139] [Cited by in F6Publishing: 135] [Article Influence: 12.6] [Reference Citation Analysis]
52 Pham LV, Tamayo AT, Li C, Bornmann W, Priebe W, Ford RJ. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications. Mol Cancer Ther 2010;9:2026-36. [PMID: 20606045 DOI: 10.1158/1535-7163.MCT-10-0238] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
53 Rozovski U, Harris DM, Li P, Liu Z, Wu JY, Grgurevic S, Faderl S, Ferrajoli A, Wierda WG, Martinez M, Verstovsek S, Keating MJ, Estrov Z. At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells. J Immunol 2016;196:4400-9. [PMID: 27076684 DOI: 10.4049/jimmunol.1402108] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
54 Verstovsek S. Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. Clin Cancer Res 2010;16:1988-96. [PMID: 20215535 DOI: 10.1158/1078-0432.CCR-09-2836] [Cited by in Crossref: 33] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
55 Phi JH, Choi SA, Kim SK, Wang KC, Lee JY, Kim DG. Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling. Transl Oncol 2015;8:376-86. [PMID: 26500028 DOI: 10.1016/j.tranon.2015.08.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
56 Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells. Oncotarget 2018;9:33710-8. [PMID: 30263097 DOI: 10.18632/oncotarget.26110] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
57 Honda S, Sadatomi D, Yamamura Y, Nakashioya K, Tanimura S, Takeda K. WP1066 suppresses macrophage cell death induced by inflammasome agonists independently of its inhibitory effect on STAT3. Cancer Sci 2017;108:520-7. [PMID: 28035720 DOI: 10.1111/cas.13154] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]